Quotient Therapeutics
Transforming genetically-validated targets into breakthrough medicines
About Quotient Therapeutics
Quotient Therapeutics develops breakthrough medicines informed by natural somatic genetic diversity present in patients. Through integrated somatic genomics and computational technologies, the company gains unbiased, unprecedented resolution into disease-causal drug targets that it leverages to design and develop first-in-class therapies.
Industry
Biotechnology
Headquarters
Cambridge, Massachusetts, USA
Company size
51-100
Founded
2022
What we do
Somatic genomicsDrug target discoveryComputational biologyTranslational medicine
Interested in Quotient Therapeutics?
Join our talent pool to be considered for future opportunities.